Johnson & Johnson · NYSE:JNJ
Johnson & Johnson — Shockwave Medical — Merger or Acquisition (April 2024)
21 slides from Johnson & Johnson's merger presentation, Apr 5, 2024
Slide 1: Johnson & Johnson + Shockwave Medical Investor Presentation
Johnson & Johnson + Shockwave Medical Investor Presentation April 5, 2024
Slide 2: Cautions Concerning Forward-Looking Statements
Cautions Concerning Forward-Looking Statements This communication contains “forward-looking statements” regarding the acquisition of Shockwave by Johnson & Johnson. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future e
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of the proposed acquisition of Shockwave Medical by Johnson & Johnson. In connection with the proposed transaction, Shockwave intends to file relevant materials with the U.S. Securitie
Slide 4: Agenda and Today's Speakers
Agenda Today’s Speakers CEO Remarks Shockwave Medical Overview Strategic Rationale Financial Impact Joaquin Duato Tim Schmid Joe Wolk Q&A Chairman and Chief Executive Executive Vice President, Executive Vice President, Officer Worldwide Chairman, MedTech Chief Financial Officer Doug Godshall Preside
Slide 5: Joaquin Duato
Joaquin Duato Chairman and Chief Executive Officer, Johnson & Johnson 5
Slide 6: Enhancing our Impact in Cardiovascular Health
Enhancing our Impact in Cardiovascular Health Strengthens J&J presence in high-growth cardiovascular segments Complementary fit with Abiomed heart recovery platform Advances standard of care for patients with cardiovascular disease by growing global reach and scale Shockwave Medical’s segment-leadin
Slide 7: Our Credo
Notre Credo Neogene setters at Semi ee det ‘hide tae tes etn SCtenane pono pete tan to ae] ee else. Sve PE Johnson&Johnson BIER Bom os. BE fo. nM eUCHR, Teeeants. BR) FRcOnBSRAEAL roamed. 83) femnevannies Raounieonl. © (eae arnis aronaomes. Kenacnreeo: aoeeoce. ser iBAReReLG! qamaacest, pert. paoaen
Slide 8: Doug Godshall
Doug Godshall President and Chief Executive Officer, Shockwave Medical 8
Slide 9: IVL helps treat calcified arteries
IVL helps treat calcified arteries How does it work? What is intravascular lithotripsy? IVL is a catheter-based treatment for calcified arterial lesions, 1 A catheter is delivered across a calcified lesion over a wire and a balloon is expanded which can reduce blood flow and cause pain or heart atta
Slide 10: Shockwave Medical Overview
Shockwave Medical Overview A premier medtech growth company transforming the Shockwave Medical today treatment landscape with innovative technologies ~$0.7B Sales (~70% CAD, ~30% PAD) ~50% Intravascular Lithotripsy (IVL) Robust R&D pipeline YoY Growth (2022-23) Shockwave’s first-to-market technology
Slide 11: Shockwave Medical's Current Portfolio and Pipeline
Shockwave Medical’s Current Portfolio and Pipeline Foundational products established IVL as a safe and effective solution for calcified arterial lesions Peripheral Coronary 27 Developmental Programs in 2023 Shockwave L6 (30mm) FDA 510(k) clearance in 2022 Shockwave C2 (12mm) CE Mark in 2018 8 Early
Slide 12: Tim Schmid
Tim Schmid Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson 12
Slide 13: Cardiovascular disease
Cardiovascular disease #1 $70B 26M CARDIOVASCULAR cause of death direct medical costs total patients worldwide DISEASE presents one of the largest and most pressing healthcare ALL forms of cardiovascular disease lead to heart failure, which is the issues of our lifetime #1 #1 cause of hospitalizatio
Slide 14: Extends JJMT Position in High-Growth Cardiovascular Segments
Extends JJMT Position in High-Growth Cardiovascular Segments PIPELINE OPPORTUNITY Electrophysiology 13% Heart recovery 14% IVL – coronary 20%+ IVL – peripheral ~20% LAAC 20%+ 2023-26 Market 2023-26 Market 2023-26 Market 2023-26 Market 2023-26 Market CAGR CAGR CAGR CAGR CAGR Market Leader: Market Lea
Slide 15: Leveraging Johnson & Johnson's Capabilities to Accelerate Growth
Leveraging Johnson & Johnson’s Capabilities to Accelerate Growth Global Footprint Complementary Strong Professional Deep Regulatory and Well Established to Support OUS with Abiomed Education Market Access Health System and Expansion Technology Capabilities Expertise Physician Relationships 15
Slide 16: Joe Wolk
Joe Wolk Executive Vice President, Chief Financial Officer, Johnson & Johnson 16
Slide 17: Transaction Bolsters Growth Platform
Transaction Bolsters Growth Platform Accelerates revenue growth for Johnson & Johnson and Johnson & Johnson MedTech Accretive to operating margin for Johnson & Johnson and Johnson & Johnson MedTech Dilutive to adj. EPS by ~$0.10 in 2024 and ~$0.17 in 2025, considering impact of financing costs 17
Slide 18: Transaction Details and Path to Close
Transaction Details and Path to Close Expected to close by mid-year 2024 Transaction • $335.00 per share in cash Structure • $13.1 billion enterprise value including cash acquired Sources of • Expected to be funded through combination of cash on hand and Financing debt • Expected to maintain strong
Slide 19: Johnson & Johnson + Shockwave Medical Highlights
Johnson & Johnson + Shockwave Medical Highlights Aligns with Brings lifesaving Johnson & Johnson innovations to more strategic priorities patients with unmet needs Accelerates growth Compelling for of Johnson & Johnson and both Shockwave Medical Johnson & Johnson and Johnson & Johnson MedTech shareh
Slide 20: Questions
Questions Johnson&Johnson
Slide 21: Thank You
Johnson&Johnson
Shockwave Medical — Merger or Acquisition (April 2024) on 6ix